Примери за използване на Months after treatment на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Women of childbearing potential should be using two methods of effective contraception during treatment with brentuximab vedotin and until 6 months after treatment.
with serum thyroglobulin testing at 8± 1 months after treatment.
The prescriber should examine the patient monthly during and up to six months after treatment for cuSCC.
Woman of childbearing potential have to use adequate contraception methods during treatment and up to 5 months after treatment.
did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
Guidance on the need to measure immune response at baseline and at 6 and 12 months after treatment.
With three simple steps its nutrient-rich formula increases elasticity and combing up to three months after treatment.
women receiving Bortezomib Accord must use effective contraception during and for up to 3 months after treatment.
Men in fertile age must use effective contraception during treatment and 5 months after treatment(see section 4.6).
Men should be advised to practice barrier contraceptive methods during and for 3 months after treatment with cidofovir(see sections 4.6 and 5.3).
Therefore, effective contraception during treatment and up to 8 months after treatment should be used in women who are able to get pregnant.
The procedure takes around 30-45 minutes and patients can expect to notice the effects for as long as 18 months after treatment.
you can expect to notice the effects for as long as 18 months after treatment.
Men should be advised to practice barrier contraceptive methods during and for 3 months after treatment with cidofovir(see section 4.4).
Six patients who achieved therapeutic response 6 months after treatment with Aclasta and later experienced disease relapse during the extended follow-up period were re-treated with Aclasta after a mean time of 6.5 years from initial treatment to re-treatment.
Six patients who achieved therapeutic response 6 months after treatment with zoledronic acid
male patients are advised not to father a child during and for up to six months after treatment with Busilvex.
Assessment of postprandial chylomicron metabolism in at least 12 patients before 12 months and 24 months after treatment with Glybera to be chosen in addition to the patients included in study CT-AMT.011.02; and eight healthy subjects in the second study.
had disease progression at least 12 months after treatment with a platinum-containing neoadjuvant
did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.